VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in Baird’s 2021 Global Healthcare Conference on September 14, 2021, at 12:10 p.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in Baird’s 2021 Global Healthcare Conference on September 14, 2021, at 12:10 p.m. PT. CEO Shawn Singh will lead a fireside chat and engage in one-on-one meetings during the two-day event. A live webcast of the presentation will be available on the Investors section of VistaGen's website. The company focuses on developing innovative medicines for anxiety, depression, and other CNS disorders, with three drug candidates currently showing promise in clinical studies.
Details
News Market Reaction – VTGN
The recorded move for VTGN in the trading session of this news was -0.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in Baird’s 2021 Global Healthcare Conference, including a fireside chat with Shawn Singh, Chief Executive Officer, on Tuesday, September 14 at 12:10 p.m. Pacific Time and one-on-one meetings throughout the two-day conference.
A live webcast of VistaGen’s presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com.
About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.
VistaGen Company Contacts
Media:
Mark McPartland
Phone: (650) 577-3606
Email: IR@vistagen.com
Investors:
Mark Flather
Phone: (650) 577-3617
Email: IR@vistagen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.